Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARNA Arena Pharmaceuticals	$99.99	$97.65	$45.50 ▼ $100.00	$6.17B	0.55	1.56 million shs	107 shs
BIIB Biogen	$124.76 -1.8%	$124.94	$110.04 ▼ $238.00	$18.61B	0.14	1.43 million shs	1.19 million shs
NBIX Neurocrine Biosciences	$125.80 -0.6%	$116.55	$84.23 ▼ $157.98	$12.52B	0.24	1.14 million shs	1.06 million shs
UTHR United Therapeutics	$286.39 -1.5%	$301.03	$266.98 ▼ $417.82	$13.11B	0.57	451,587 shs	811,893 shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARNA Arena Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
BIIB Biogen	-1.79%	-4.79%	-0.83%	-10.35%	-44.30%
NBIX Neurocrine Biosciences	-0.59%	+0.64%	+4.68%	+8.28%	-6.52%
UTHR United Therapeutics	-1.50%	-0.75%	-6.91%	-9.58%	-9.38%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARNA Arena Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BIIB Biogen	4.7974 of 5 stars	4.2	3.0	0.0	3.7	2.6	1.7	2.5
NBIX Neurocrine Biosciences	4.7251 of 5 stars	4.4	3.0	0.0	2.9	2.1	2.5	1.9
UTHR United Therapeutics	4.987 of 5 stars	4.3	5.0	0.0	4.6	2.8	3.3	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARNA Arena Pharmaceuticals	0.00	N/A	N/A	N/A
BIIB Biogen	2.38	Hold	$188.19	50.84% Upside
NBIX Neurocrine Biosciences	2.86	Moderate Buy	$162.00	28.78% Upside
UTHR United Therapeutics	2.69	Moderate Buy	$393.08	37.25% Upside

Current Analyst Ratings Breakdown

Latest ARNA, BIIB, UTHR, and NBIX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2025	BIIB Biogen	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$115.00
6/12/2025	BIIB Biogen	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$121.00
6/12/2025	BIIB Biogen	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
6/11/2025	UTHR United Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$321.00 ➝ $315.00
6/2/2025	NBIX Neurocrine Biosciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$145.00
6/2/2025	UTHR United Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$405.00
5/7/2025	BIIB Biogen	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$207.00 ➝ $169.00
5/6/2025	NBIX Neurocrine Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
5/6/2025	NBIX Neurocrine Biosciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$137.00 ➝ $145.00
5/6/2025	NBIX Neurocrine Biosciences	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$160.00 ➝ $154.00
5/6/2025	NBIX Neurocrine Biosciences	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$137.00 ➝ $152.00

(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARNA Arena Pharmaceuticals	$50K	123,305.67	N/A	N/A	$10.94 per share	9.14
BIIB Biogen	$9.68B	1.89	$22.68 per share	5.50	$114.71 per share	1.09
NBIX Neurocrine Biosciences	$2.36B	5.29	$3.36 per share	37.44	$25.58 per share	4.92
UTHR United Therapeutics	$2.88B	4.49	$27.97 per share	10.24	$144.34 per share	1.98

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARNA Arena Pharmaceuticals	-$616.43M	-$10.13	N/A	N/A	N/A	N/A	-69.83%	-62.35%	N/A
BIIB Biogen	$1.63B	$10.13	12.32	7.56	1.00	15.07%	14.03%	8.32%	7/30/2025 (Estimated)
NBIX Neurocrine Biosciences	$341.30M	$2.95	42.64	19.44	1.30	12.68%	11.81%	8.59%	7/30/2025 (Estimated)
UTHR United Therapeutics	$1.20B	$25.06	11.43	10.42	6.36	40.44%	19.33%	16.73%	7/30/2025 (Estimated)

Latest ARNA, BIIB, UTHR, and NBIX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/5/2025	Q1 2025	NBIX Neurocrine Biosciences	$0.70	$0.08	-$0.62	$0.08	$587.06 million	$572.60 million
5/1/2025	Q1 2025	BIIB Biogen	$3.26	$3.02	-$0.24	$1.64	$2.25 billion	$2.43 billion
4/30/2025	Q1 2025	UTHR United Therapeutics	$6.29	$6.63	+$0.34	$6.63	$726.82 million	$794.40 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARNA Arena Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
NBIX Neurocrine Biosciences	N/A	N/A	N/A	N/A	N/A
UTHR United Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARNA Arena Pharmaceuticals	0.05	8.59	8.59
BIIB Biogen	0.27	1.44	1.01
NBIX Neurocrine Biosciences	N/A	3.13	3.02
UTHR United Therapeutics	N/A	5.46	5.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARNA Arena Pharmaceuticals	83.77%
BIIB Biogen	87.93%
NBIX Neurocrine Biosciences	92.59%
UTHR United Therapeutics	94.08%

Insider Ownership

Company	Insider Ownership
ARNA Arena Pharmaceuticals	2.41%
BIIB Biogen	0.18%
NBIX Neurocrine Biosciences	4.30%
UTHR United Therapeutics	10.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARNA Arena Pharmaceuticals	448	61.66 million	60.17 million	Optionable
BIIB Biogen	7,605	146.53 million	146.26 million	Optionable
NBIX Neurocrine Biosciences	1,800	98.97 million	94.71 million	Optionable
UTHR United Therapeutics	1,305	45.11 million	40.46 million	Optionable

ARNA, BIIB, UTHR, and NBIX Headlines

Recent News About These Companies

United Therapeutics Corporation Concludes Enrollment of the ADVANCE OUTCOMES Study of Ralinepag for the Treatment of Pulmonary Arterial Hypertension

June 23 at 7:00 AM | businesswire.com

United Therapeutics Corporation (NASDAQ:UTHR) Receives Average Recommendation of "Moderate Buy" from Analysts

June 23 at 2:26 AM | marketbeat.com

Retirement Systems of Alabama Sells 11,423 Shares of United Therapeutics Corporation (NASDAQ:UTHR)

June 21 at 4:48 AM | marketbeat.com

CWA Asset Management Group LLC Raises Holdings in United Therapeutics Corporation (NASDAQ:UTHR)

June 19, 2025 | marketbeat.com

United Therapeutics Corporation (NASDAQ:UTHR) EVP Sells $3,079,560.00 in Stock

June 19, 2025 | americanbankingnews.com

Great Lakes Retirement Inc. Acquires Shares of 4,014 United Therapeutics Co. (NASDAQ:UTHR)

June 17, 2025 | marketbeat.com

United Therapeutics Co. (NASDAQ:UTHR) EVP Sells $3,079,560.00 in Stock

June 17, 2025 | insidertrades.com

Paul A. Mahon Sells 11,000 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock

June 16, 2025 | marketbeat.com

328,783 Shares in United Therapeutics Co. (NASDAQ:UTHR) Bought by Vaughan Nelson Investment Management L.P.

June 15, 2025 | marketbeat.com

SG Americas Securities LLC Grows Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

June 14, 2025 | marketbeat.com

Tobam Sells 11,834 Shares of United Therapeutics Co. (NASDAQ:UTHR)

June 13, 2025 | marketbeat.com

3,900 Shares in United Therapeutics Co. (NASDAQ:UTHR) Purchased by Polianta Ltd

June 13, 2025 | marketbeat.com

Greenwood Capital Associates LLC Acquires Shares of 2,349 United Therapeutics Co. (NASDAQ:UTHR)

June 13, 2025 | marketbeat.com

Assenagon Asset Management S.A. Purchases 10,290 Shares of United Therapeutics Co. (NASDAQ:UTHR)

June 13, 2025 | marketbeat.com

United Therapeutics (UTHR) Soars 3.5%: Is Further Upside Left in the Stock?

June 13, 2025 | zacks.com

United Therapeutics (NASDAQ:UTHR) Price Target Cut to $315.00 by Analysts at Bank of America

June 11, 2025 | marketbeat.com

United Therapeutics: Tanking On Rival's PAH Data - I'd Consider Buying Stock

June 11, 2025 | seekingalpha.com

United Therapeutics: Strong Market Position and Growth Potential Amidst Emerging Competition

June 11, 2025 | tipranks.com

James Edgemond Sells 12,000 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock

June 10, 2025 | marketbeat.com

Insmed Stock Soars on Pulmonary Arterial Hypertension Drug Trial Results

June 10, 2025 | msn.com

United Therapeutics (NASDAQ:UTHR) Shares Gap Down - Here's What Happened

June 10, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARNA, BIIB, UTHR, and NBIX Company Descriptions

Arena Pharmaceuticals NASDAQ:ARNA

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.

Biogen NASDAQ:BIIB

$124.76 -2.28 (-1.79%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$125.40 +0.64 (+0.52%)

As of 06/23/2025 07:37 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Neurocrine Biosciences NASDAQ:NBIX

$125.80 -0.75 (-0.59%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$125.28 -0.52 (-0.42%)

As of 06/23/2025 07:00 PM Eastern

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

United Therapeutics NASDAQ:UTHR

$286.39 -4.36 (-1.50%)

Closing price 06/23/2025 04:00 PM Eastern

Extended Trading

$286.04 -0.34 (-0.12%)

As of 06/23/2025 07:45 PM Eastern

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time